Research

Mixed

Roux-en-Y gastric bypass (RYGB) surgery is the only treatment for morbid obesity that conveys substantial and sustained weight loss and long-term remission of obesity-related comorbidities, whereas lifestyle interventions have failed to reduce cardiovascular event rates in obese patients with type 2 diabetes.

For individuals with morbid obesity (BMI >40 or >35 with comorbidities), lifestyle interventions alone are insufficient for sustained weight loss and cardiovascular risk reduction. Bariatric surgery, specifically Roux-en-Y gastric bypass, is identified as the only treatment providing substantial, sustained weight loss and remission of comorbidities.

ModerateSupportsMEDIUM confidence
Currently, bariatric surgery is the only treatment for morbid obesity conveying a substantial and sustained weight loss and long-term remission of obesity-related comorbidities... Lifestyle intervention was not able to reduce the rate of cardiovascular events in obese patients with type 2 diabetes (16), but mortality might be reduced by bariatric surgery (11, 17).
Ann-Cathrin Koschker et al. · Endocrine Connections · 2022

Why this rating

The paper is a study design/baseline report; it cites registry data and meta-analyses for the claim but does not present its own outcome data yet.

Source

Cardio-psycho-metabolic outcomes of bariatric surgery: design and baseline of the WAS trial

Ann-Cathrin Koschker et al. · Endocrine Connections · 2022

DOI 10.1530/ec-21-0338

rct · n=93Cited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →